Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.

ABSTRACT:

Background

Dermatoses are common and potentially serious complications of programmed cell death receptor PD-1 immune checkpoint inhibitor (anti-PD-1 ICI) therapy. Understanding their incidence is necessary to support clinical awareness, diagnosis, and management.

Objective

To examine the incidence and odds of reported non-cancerous dermatoses in the setting of anti-PD-1 ICI therapy.

Methods

Cross-sectional study of anti-PD-1 (pembrolizumab or nivolumab) treated patients at a tertiary healthcare institution. Selected dermatologic events following immunotherapy were identified in the electronic medical record. Comparator arm were patients that developed these same dermatoses without receiving anti-PD-1 ICI therapy.

Results

There were 13.7% (254/1857) patients tha

SUBMITTER: Le TK 

PROVIDER: S-EPMC8458472 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature